Vol.

No.

June 08, 2018Jun 08, 2018

Free

DOWNLOAD THE PDF

Big takeaway from ASCO: 70 percent of women with early breast cancer don't benefit from adjuvant chemotherapy

Cover Story

Free

Big takeaway from ASCO:

70 percent of women with early breast cancer don't benefit from adjuvant chemotherapy

By Paul Goldberg

An NCI-sponsored trial showed that up to 70 percent of women with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer would not benefit from chemotherapy.

Conversation with The Cancer Letter Free

Abrams: Only about 20-30 percent of the group might benefit from chemotherapy

By Paul Goldberg

Free

Sharpless: NCI adds $10 million for NCTN and NCORP trials

By Matthew Bin Han Ong

Clinical Free Trials & Tribulations

Searching for Breast Cancer's “Extreme Survivors”

By Mark Burkard

In Brief

J&J Innovation and Boston University form lung cancer research alliance

Kochevar to retire from Colorado Cancer Center

Funding Opportunities

Addario, Van Auken foundations announce 2018 Young Innovators Team Award

Clinical Roundup

New treatment combination improves outcomes for some patients with colorectal cancer

Exact Sciences, Mayo Clinic identify blood-based DNA biomarkers to diagnose hepatocellular carcinoma

Opdivo demonstrates superior RFS vs. Yervoy for patients with resected stage III or IV melanoma

Opdivo plus Yervoy provide QOL improvements in RCC

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Big takeaway from ASCO:

Abrams: Only about 20-30 percent of the group might benefit from chemotherapy

Sharpless: NCI adds $10 million for NCTN and NCORP trials

Searching for Breast Cancer's “Extreme Survivors”

In Brief

J&J Innovation and Boston University form lung cancer research alliance

Kochevar to retire from Colorado Cancer Center

Funding Opportunities

Addario, Van Auken foundations announce 2018 Young Innovators Team Award

Clinical Roundup

New treatment combination improves outcomes for some patients with colorectal cancer

Exact Sciences, Mayo Clinic identify blood-based DNA biomarkers to diagnose hepatocellular carcinoma

Opdivo demonstrates superior RFS vs. Yervoy for patients with resected stage III or IV melanoma

Opdivo plus Yervoy provide QOL improvements in RCC

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login